drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous CD7-directed chimeric antigen receptor (CAR) T-cell therapy in which patient T cells are genetically engineered to express a CAR targeting CD7, enabling TCR-independent activation and cytotoxic killing of CD7-positive T/NK-cell malignancies.
nci_thesaurus_concept_id
C200796
nci_thesaurus_definition
A preparation of T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD7 CAR-T cells RD13-02 specifically target and kill CD7-expressing tumor cells. CD7 is a transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting CD7. Upon binding CD7 on malignant T/NK cells, the CAR triggers TCR-independent activation and cytotoxic killing via perforin/granzyme release and cytokine-mediated effects, leading to elimination of CD7-positive tumor cells.
drug_name
RD13-02
nct_id_drug_ref
NCT06732492